By Steve Wood
President and CEO, Covectra
Over the last few years, prescription drug diversion and abuse has grown at alarming rates, resulting in an increase in the number of deaths and hospitalizations. Opioid addiction and abuse has become one the nation’s most serious healthcare crises. More than 23,000 people die each year from prescription drug abuse—more than are killed in traffic incidents.
Acsis Inc. reports that Daiichi Sankyo Inc. has selected the Acsis Serialization Management Suite for use at the company's packaging plant in Bethlehem, PA. Acsis will manage implementation and support as Daiichi Sankyo begins using the solution initially as a pilot toward full compliance with electronic pedigree mandates and other regulations. Acsis's serialization management solution will be coupled with vision and printing equipment from Cognex and Domino.
Pharma serialization solutions provider Systech International is adding two professionals to its Board of Directors, John Bailye and Michael Fawkes. “We are delighted to welcome new members to our Board, John Bailye and Michael Fawkes, who bring a vast amount of industry experience and business acumen upon which Systech will draw as we continue to grow,” said Robert DeJean, President and CEO, Systech International, in a press release.
During its public board meeting on December 13, the California State Board of Pharmacy discussed written and oral comments provided in response to the first proposed regulations needed to implement the state’s electronic drug pedigree provisions.
In July, dozens of people were charged in New York City for diverting and trafficking prescription drugs for treating HIV that were paid for by Medicaid, in some cases twice. Diverters reportedly purchased prescribed drugs from Medicaid beneficiaries, removed patient labeling from bottles, and added counterfeit labels as needed to redistribute the drugs back in the supply chain. According to a press release issued by the U.S.
Inference refers to inferring “the contents of a case, pallet, or other aggregate of individual units, packages, or containers of dangerous drugs, from a unique identifier associated with the case, pallet, or other aggregate, without opening each case, pallet, or other aggregate or otherwise individually validating each unit,” according to the California State Board of Pharmacy (CA BoP).